Innovative Technologies
Commercialized Science
  • About Qualigen

    Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform.  The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002.  Our therapeutics pipeline includes cancer drug compounds such as AS1411, AS1411-GNP and RAS-F, as well as STARS, a DNA/RNA-based treatment device.  By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville,  we are committed to providing exciting new therapeutic technologies to physicians and patients.

  • Our Technology

    Qualigen’s AS1411 cancer drug uses a specialized segment of DNA, known as an aptamer, to target and destroy tumor cells, without the serious side effects associated with other cancer therapies .  Our AS1411-GNP cancer drug combines this DNA aptamer with gold nanoparticle technology to increase its potency and broaden the potential applications to include combination therapy with radiation and tumor imaging.   The STARS device will use aptamer technology to cleanse a patient’s blood of circulating tumor cells, checkpoints and inflammation factors.  STARS can also be used for infectious disease treatment, where it can capture and remove viruses.  RAS-F is a small-molecule drug designed to inhibit a genetic mutation that can turn a normal cell into a tumor cell.   The company’s flagship product line, FastPack®, combines magnetic particle immunochemistry with innovative disposable packaging technology to provide real-time diagnostic information for cancers and other serious medical conditions.

  • News

    April 11, 2019

    Qualigen Enters into Research Agreement for RAS Inhibitor Cancer Drug with University of Louisville (UofL)

    Qualigen, Inc., and the University of Louisville (UofL) today announced that Qualigen has entered into a Sponsored Research Agreement (SRA) with UofL for development of several small-molecule RAS Inhibitor drug candidates.  Under the terms of this Sponsored Research Agreement, Qualigen assumed funding responsibility for this program from April 1, 2019 through September 30, 2020.  RAS…

    January 29, 2019

    Qualigen Receives FDA Clearance for its FastPack® IP SHBG Assay

    Qualigen, Inc., a privately-owned company that provides novel diagnostic and therapeutic technologies for the treatment of cancer and infectious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration for its FastPack IP Sex Hormone Binding Globulin (SHBG) Immunoassay.  Sex Hormone Binding Globulin is an important biomarker used in…

    January 3, 2019

    UofL: Hub for Research, Innovation, Collaboration

    “UofL Cancer Researcher Paula Bates creates life changing products that have companies including Qualigen reaching out to buy licenses for UofL based discoveries” Video: